KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Current Leases (2020 - 2025)

Adaptive Biotechnologies (ADPT) has disclosed Current Leases for 6 consecutive years, with $8.9 million as the latest value for Q4 2025.

  • Quarterly Current Leases fell 12.88% to $8.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.9 million through Dec 2025, down 12.88% year-over-year, with the annual reading at $8.9 million for FY2025, 12.88% down from the prior year.
  • Current Leases hit $8.9 million in Q4 2025 for Adaptive Biotechnologies, down from $9.4 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $10.5 million in Q1 2025 to a low of $4.3 million in Q1 2021.
  • Historically, Current Leases has averaged $8.5 million across 5 years, with a median of $9.3 million in 2023.
  • Biggest five-year swings in Current Leases: surged 186.82% in 2021 and later decreased 12.88% in 2025.
  • Year by year, Current Leases stood at $5.1 million in 2021, then soared by 82.59% to $9.2 million in 2022, then increased by 1.67% to $9.4 million in 2023, then rose by 9.11% to $10.2 million in 2024, then fell by 12.88% to $8.9 million in 2025.
  • Business Quant data shows Current Leases for ADPT at $8.9 million in Q4 2025, $9.4 million in Q3 2025, and $10.0 million in Q2 2025.